Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468072 | 0.71 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL6463169 | 0.71 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL11619011 | 0.66 | CES2 (0.47) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28159836 | 0.65 | NPC1 (0.42) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15120382 | 0.64 | CES2 (0.56) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29232767 | 0.64 | ALDH1A1 (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3732383 | 0.62 | CES2 (0.58) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3181932 | 0.62 | CES2 (0.58) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27923715 | 0.62 | CYP2C19 (0.53) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| Triacetin SCHEMBL28159835 | 0.62 | ALDH1A1 (0.43) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | BOARD OF REGENTS | 2005-01-06 | — | — | US | disclosed |
| US-6753414-B2 | PREPARING NATURALLY OCCURRING SAPONINS SUCH AS OSW-L | UNIVERSITY OF IOWA RESEARCH FOUNDATION, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030069214-A1 | Process for preparing saponin compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069214-A1 | Process for preparing saponin compounds | LSS, CYP51A1, CYP4F11 | NPC1 305/4885RAB9A 668/4885ALDH1A1 1740/4885 |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | OSBP2, OSBP, OSBPL3 | NPC1 3107/4885RAB9A 4139/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.